CBP to Launch Phase 3 for CAPE Processing of IEEPA Refunds October 6

This phase applies to finally liquidated entries subject to IEEPA duties where importers filed lawsuits with the Court of International Trade (CIT) and obtained a court order requiring reliquidation.

gov.uscourts.cit.19175.50.0.pdf

CSMS # 70054007 - UPDATED GUIDANCE: Section 232 Duties on Imports of Pharmaceutical Articles and Ingredients: U.S. Customs and Border Protection issued guidance for implementing Section 232 duties on pharmaceutical imports under Proclamation 11020. The update clarifies product definitions, adds a new HTSUS provision (9903.04.70) for clinical trials, R&D, and other non-commercial pharmaceutical uses at a 0% duty rate, expands the definition of generic pharmaceuticals to include unpatented animal health products, and makes several technical HTSUS corrections. Effective September 29, 2026, patented pharmaceutical products generally face a 100% additional duty (HTSUS 9903.04.60), although reduced or zero-duty treatment applies in certain situations, including qualifying products from the UK (0%), Japan/EU/South Korea/Switzerland/Liechtenstein (15%), products covered by onshoring agreements, generic pharmaceuticals, certain specialty drugs from designated countries, U.S.-origin API products, and non-commercial research products.

Section 232 Pharmaceuticals HTS List

IEEPA Refund Processing Services

Email your request to: Customs_Compliance_Group@am.kwe.com and a member of our IEEPA Refund processing team will reach out to you.

ADVISORY SIGN UP – ONE FORWARDER, ONE BROKER = OVERALL COMPLIANCE

Add this link to your “Favorites”: U.S.A. - News | Kintetsu World Express

Read As PDF